JP2025510678A5 - - Google Patents
Info
- Publication number
- JP2025510678A5 JP2025510678A5 JP2024555897A JP2024555897A JP2025510678A5 JP 2025510678 A5 JP2025510678 A5 JP 2025510678A5 JP 2024555897 A JP2024555897 A JP 2024555897A JP 2024555897 A JP2024555897 A JP 2024555897A JP 2025510678 A5 JP2025510678 A5 JP 2025510678A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody conjugate
- conjugate according
- pharmaceutically acceptable
- antibody
- fuc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22163928.9 | 2022-03-23 | ||
| EP22163928 | 2022-03-23 | ||
| PCT/EP2023/057565 WO2023180489A1 (en) | 2022-03-23 | 2023-03-23 | Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510678A JP2025510678A (ja) | 2025-04-15 |
| JP2025510678A5 true JP2025510678A5 (enExample) | 2026-04-01 |
Family
ID=80930396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024555897A Pending JP2025510678A (ja) | 2022-03-23 | 2023-03-23 | カルシノエンビロニック抗原を発現する腫瘍を標的化するための抗体コンジュゲート |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250082770A1 (enExample) |
| EP (1) | EP4496595A1 (enExample) |
| JP (1) | JP2025510678A (enExample) |
| KR (1) | KR20250024741A (enExample) |
| CN (1) | CN119233830A (enExample) |
| AU (1) | AU2023237620A1 (enExample) |
| CA (1) | CA3254964A1 (enExample) |
| IL (1) | IL315205A (enExample) |
| MX (1) | MX2024011519A (enExample) |
| WO (1) | WO2023180489A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020094670A1 (en) | 2018-11-05 | 2020-05-14 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
| IL315366A (en) | 2022-03-23 | 2024-11-01 | Synaffix Bv | Antibody pairs for targeting PTK7-expressing tumors |
| WO2025005240A1 (ja) * | 2023-06-30 | 2025-01-02 | 第一三共株式会社 | 活性炭材料を使用する精製工程を含む抗体－薬物コンジュゲートの製造方法 |
| WO2025238253A1 (en) * | 2024-05-16 | 2025-11-20 | Synaffix B.V. | Antibody-oligonucleotide conjugates |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4939255A (en) | 1987-06-24 | 1990-07-03 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic camptothecin derivatives |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| GB9317423D0 (en) | 1993-08-21 | 1993-10-06 | Imp Cancer Res Tech | Monoclonal antibodies |
| GB9324807D0 (en) | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| GB9621295D0 (en) | 1995-12-07 | 1996-11-27 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| US7232888B2 (en) | 2002-07-01 | 2007-06-19 | Massachusetts Institute Of Technology | Antibodies against tumor surface antigens |
| EP1572131B1 (en) | 2002-10-08 | 2016-07-06 | Immunomedics, Inc. | Antibody therapy |
| US7273608B2 (en) | 2004-03-11 | 2007-09-25 | City Of Hope | Humanized anti-CEA T84.66 antibody and uses thereof |
| PT1976880T (pt) | 2005-12-21 | 2016-09-28 | Amgen Res Munich Gmbh | Composições farmacêuticas com resistência a cea solúvel |
| WO2008029281A2 (en) | 2006-02-10 | 2008-03-13 | Invitrogen Corporation | Labeling and detection of post translationally modified proteins |
| WO2009102820A2 (en) | 2008-02-11 | 2009-08-20 | Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services | Modified sugar substrates and methods of use |
| AU2010288469A1 (en) | 2009-08-31 | 2012-03-01 | Roche Glycart Ag | Affinity-matured humanized anti CEA monoclonal antibodies |
| CA2813133C (en) | 2010-10-01 | 2023-10-31 | National Research Council Of Canada | Anti-ceacam6 antibodies and uses thereof |
| ES2657856T3 (es) | 2011-03-02 | 2018-03-07 | Roche Glycart Ag | Anticuerpos CEA |
| ES2659270T5 (en) | 2012-10-23 | 2026-02-11 | Synaffix Bv | Modified antibody, antibody-conjugate and process for the preparation thereof |
| HRP20170743T1 (hr) | 2012-11-20 | 2017-07-28 | Sanofi | Anti-ceacam5 protutijela i njihova uporaba |
| HK1216176A1 (zh) * | 2012-12-21 | 2016-10-21 | Medlmmune Limited | 用於治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| CA2924398A1 (en) * | 2013-11-05 | 2015-05-14 | Immunomedics, Inc. | Humanized anti-ceacam5 antibody and uses thereof |
| KR20170030648A (ko) | 2014-08-04 | 2017-03-17 | 시나픽스 비.브이. | 베타-(1,4)-n-아세틸갈락토오스아미닐트랜스퍼라아제, 또는 이의 돌연변이체를 이용한 당 단백질의 변형 방법 |
| ES2740907T3 (es) | 2014-10-03 | 2020-02-07 | Synaffix Bv | Enlazador de sulfamida, conjugados de los mismos y métodos de preparación |
| HUE048111T2 (hu) | 2015-03-23 | 2020-05-28 | Bayer Pharma AG | Anti-CEACAM6 ellenanyagok és alkalmazásuk |
| HUE038511T2 (hu) | 2015-04-23 | 2018-10-29 | Synaffix Bv | (1,4)-N-acetil-galaktóz-aminil-transzferáz vagy (1,4)-N-acetil-galaktóz-aminil-transzferázból származó glikoziltranszferázt alkalmazó, glikoprotein módosítására szolgáló eljárás |
| WO2017137457A1 (en) * | 2016-02-08 | 2017-08-17 | Synaffix B.V. | Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates |
| US11951175B2 (en) * | 2016-02-08 | 2024-04-09 | Synaffix B.V. | Bioconjugates containing sulfamide linkers for use in treatment |
| CN108883191B (zh) * | 2016-02-08 | 2022-10-14 | 西纳福克斯股份有限公司 | 用于靶向cd30肿瘤的具有改善的治疗指数的抗体-缀合物以及用于改善抗体-缀合物的治疗指数的方法 |
| WO2017214491A1 (en) | 2016-06-09 | 2017-12-14 | Blinkbio, Inc. | Silanol based therapeutic payloads |
| EP3720504A1 (en) | 2017-12-06 | 2020-10-14 | Synaffix B.V. | Enediyne conjugates |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| CR20210541A (es) | 2019-03-29 | 2021-12-20 | Medimmune Ltd | Compuestos y conjugados de estos |
| HUE065484T2 (hu) | 2019-04-26 | 2024-05-28 | Immunogen Inc | Camptothecin-származékok |
| BR112022004995A2 (pt) | 2019-09-18 | 2022-06-21 | Lamkap Bio Alpha AG | Anticorpos biespecíficos contra ceacam5 e cd3 |
| CN116209679A (zh) | 2020-06-05 | 2023-06-02 | 财团法人生物技术开发中心 | 含有抗间皮素抗体的抗体-药物共轭物及其用途 |
| NL2026947B1 (en) | 2020-11-20 | 2022-07-01 | Synaffix Bv | Tyrosine-based antibody conjugates |
| CN113816969B (zh) | 2021-04-30 | 2024-01-16 | 联宁（苏州）生物制药有限公司 | 依喜替康类化合物、其抗体药物偶联物及其应用 |
| JP7451677B2 (ja) | 2021-07-19 | 2024-03-18 | 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 | 二成分毒素を担った抗体薬物複合体及びその応用 |
-
2023
- 2023-03-23 KR KR1020247034723A patent/KR20250024741A/ko active Pending
- 2023-03-23 AU AU2023237620A patent/AU2023237620A1/en active Pending
- 2023-03-23 CA CA3254964A patent/CA3254964A1/en active Pending
- 2023-03-23 CN CN202380028865.6A patent/CN119233830A/zh active Pending
- 2023-03-23 EP EP23715080.0A patent/EP4496595A1/en active Pending
- 2023-03-23 MX MX2024011519A patent/MX2024011519A/es unknown
- 2023-03-23 IL IL315205A patent/IL315205A/en unknown
- 2023-03-23 WO PCT/EP2023/057565 patent/WO2023180489A1/en not_active Ceased
- 2023-03-23 JP JP2024555897A patent/JP2025510678A/ja active Pending
-
2024
- 2024-09-20 US US18/892,256 patent/US20250082770A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025510623A5 (enExample) | ||
| EP0180564B1 (en) | Immunogenic complex, a method for producing the same, and the use thereof as an immune stimulant, vaccines and reagents | |
| US5391723A (en) | Oligonucleotide conjugates | |
| JP2023534131A5 (enExample) | ||
| JP2020114818A5 (enExample) | ||
| Jennings et al. | Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. | |
| Baldo et al. | C-reactive protein-like precipitins in plaice | |
| JP5933923B2 (ja) | 新規な複合タンパク質及びペプチド | |
| US6800728B2 (en) | Hydrazine-based and carbonyl-based bifunctional crosslinking reagents | |
| JP2024028453A5 (enExample) | ||
| JP2024010112A5 (enExample) | ||
| JP2002513028A (ja) | ポリサッカリド抗原結合体 | |
| JP2021517113A5 (enExample) | ||
| JP2001506990A (ja) | 一価の（ｍｏｎｏｖａｌｅｎｔ）抗体フラグメント | |
| IE58088B1 (en) | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency | |
| EP0206852A1 (fr) | Conjugué constitué d'une adhésine de paroi de Streptococcus mutans, de nature protéique et d'un polysaccharide de Streptococcus mutans, sa préparation et son utilisation notamment dans des vaccins anti-caries | |
| JP2012021161A (ja) | シアニン色素 | |
| JP2025060958A5 (enExample) | ||
| JPH01230592A (ja) | Ｔ―抗原決定基を有する免疫吸着剤 | |
| JP2006514627A5 (enExample) | ||
| JP2002504096A (ja) | タンパク質−多糖ワクチンの調製のための未修飾タンパク質とハロアシルまたはジハロアシル誘導体化された多糖との結合 | |
| JP2005530493A5 (enExample) | ||
| JP2008518953A5 (enExample) | ||
| JP2025510700A5 (enExample) | ||
| JP2004529881A5 (enExample) |